Menstrual Migraine
14
2
3
5
Key Insights
Highlights
Success Rate
71% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
14.3%
2 terminated out of 14 trials
71.4%
-15.1% vs benchmark
29%
4 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 5 completed trials
Clinical Trials (14)
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
Evaluation of the Migraceutics® Phase-Specific Dietary Supplement Regimen on Quality of Life, Work Productivity, and Biomarkers in Adult Migraineurs: The Migraceutics® START Study
Repetitive GON Blockade for Menstrual Migraine
Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45
Fremanezumab for the Prevention of Menstrually-related Migraine Attacks
A Study Investigating the Efficacy and Safety of Sepranolone in Women With Menstrual Migraine
Efficacy and Safety of Nerivio for the Acute Treatment of Menstrual Migraine
Detecting Auricular Points in MMG by a Novel APD ( APD-MMG )
Frovatriptan and Menstrual Migraine
Saccadometry in Primary Headache Syndromes
Intracranial Pressure During Migraine
Comparison of the Prophylactic Effect Between Acupuncture and Acupressure on Menstrual Migraine
CGRP, Estrogen, Cortisol, VIP, α-Amylase, PGE2, PGI2 and ß-Endorphin Levels in Menstrual Migraine Before and After Treximet
An Investigation of the Safety and Utility of Treximet in the Treatment of Menstrual Migraine